Genetic markers of cardiovascular disease in rheumatoid arthritis

Mediators of Inflammation

Volumn 2012, Issue , 2012, Pages

  Rodríguez Rodríguez, Luis ^a,b   López Mejías, Raquel ^c   García Bermúdez, Mercedes ^b   González Juanatey, Carlos ^d   González Gay, Miguel A ^c   Martín, Javier ^b  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^c HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^d HOSPITAL XERAL CALDE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ADIPOCYTOKINE; BLOOD CLOTTING FACTOR 13; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPITOPE; FIBRINOGEN; GHRELIN RECEPTOR; HLA DRB1 ANTIGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LEPTIN; LYMPHOTOXIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NITRIC OXIDE SYNTHASE; PROTEIN TYROSINE PHOSPHATASE; RHEUMATOID FACTOR; SECONDARY LYMPHOID TISSUE CHEMOKINE; STAT4 PROTEIN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; VASCULOTROPIN A;

ALLELE; AMINO ACID SUBSTITUTION; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; ENDOTHELIAL DYSFUNCTION; GENE DELETION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEART INFARCTION; HEMOSTASIS; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84866109609     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2012/574817     Document Type: Article

References (150)

1. Gonzalez-Juanatey C., Llorca J., Testa A., Revuelta J., Garcia-Porrua C., Gonzalez-Gay M. A., Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine 2003 82 6 407 413 2-s2.0-0344413646 10.1097/01.md.0000101572.76273.60 (Pubitemid 37445043)
2. Nurmohamed M. T., Cardiovascular risk in rheumatoid arthritis. Autoimmunity Reviews 2009 8 8 663 667 2-s2.0-67349266566 10.1016/j.autrev.2009. 02.015
3. del Rincón I. D., Williams K., Stern M. P., Freeman G. L., Escalante A., High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis and Rheumatism 2001 44 12 2737 2745 (Pubitemid 34016192)
4. Boyer J. F., Gourraud P. A., Cantagrel A., Davignon J. L., Constantin A., Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Joint Bone Spine 2011 78 2 179 183 2-s2.0-79952248637 10.1016/j.jbspin.2010.07.016
5. Sattar N., McCarey D. W., Capell H., McInnes I. B., Explaining how high-grade systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003 108 24 2957 2963 2-s2.0-0346365086 10.1161/01.CIR.0000099844.31524.05 (Pubitemid 37553561)
6. Scott D. L., Wolfe F., Huizinga T. W. J., Rheumatoid arthritis. The Lancet 2010 376 9746 1094 1108 2-s2.0-77957196913 10.1016/S0140-6736(10)60826-4
7. Hansson G. K., Mechanisms of disease: inflammation, atherosclerosis, and coronary artery disease. The New England Journal of Medicine 2005 352 16 1685 1695 2-s2.0-17644412023 10.1056/NEJMra043430 (Pubitemid 40530235)
8. Pasceri V., Yeh E. T. H., A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 1999 100 21 2124 2126 2-s2.0-0033598672
9. Klareskog L., Catrina A. I., Paget S., Rheumatoid arthritis. The Lancet 2009 373 9664 659 672 2-s2.0-60249090304 10.1016/S0140-6736(09)60008-8
10. Peden J. F., Farrall M., Thirty-five common variants for coronary artery disease: the fruits of much collaborative labour. Human Molecular Genetics 2011 20 R2 R198 R205 10.1093/hmg/ddr384
11. Gonzalez-Gay M. A., Gonzalez-Juanatey C., Martin J., Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Seminars in Arthritis and Rheumatism 2005 35 1 8 17 2-s2.0-23444439778 10.1016/j.semarthrit. 2005.03.004 (Pubitemid 41111466)
12. MacGregor A. J., Snieder H., Rigby A. S., Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis and Rheumatism 2000 43 1 30 37 (Pubitemid 30368210)
13. Marenberg M. E., Risch N., Berkman L. F., Floderus B., de Faire U., Genetic susceptibility to death from coronary heart disease in a study of twins. The New England Journal of Medicine 1994 330 15 1041 1046 2-s2.0-0028330005 10.1056/NEJM199404143301503 (Pubitemid 24106561)
14. Bartoloni E., Alunno A., Bistoni O., Gerli R., How early is the atherosclerotic risk in rheumatoid arthritis? Autoimmunity Reviews 2010 9 10 701 707 2-s2.0-77955267766 10.1016/j.autrev.2010.06.001
15. Gonzalez-Gay M. A., Gonzalez-Juanatey C., Vazquez-Rodriguez T. R., Martin J., Llorca J., Endothelial dysfunction, carotid intima-media thickness, and accelerated atherosclerosis in rheumatoid arthritis. Seminars in Arthritis and Rheumatism 2008 38 2 67 70 2-s2.0-52149115410 10.1016/j.semarthrit.2008.02.001
16. Kerekes G., Soltész P., Nurmohamed M. T., Gonzalez-Gay M. A., Turiel M., Végh E., Shoenfeld Y., McInnes I., Szekanecz Z., Validated methods for assessment of subclinical atherosclerosis in rheumatology. Nature Reviews Rheumatology 2012 8 4 224 234 2-s2.0-84859439662 10.1038/nrrheum.2012.16
17. Gonzalez-Juanatey C., Llorca J., Martin J., Gonzalez-Gay M. A., Carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis. Seminars in Arthritis and Rheumatism 2009 38 5 366 371 2-s2.0-62849085193 10.1016/j.semarthrit.2008.01.012
18. Evans M. R., Escalante A., Battafarano D. F., Freeman G. L., O'Leary D. H., del Rincõn I., Carotid atherosclerosis predicts incident acute coronary syndromes in rheumatoid arthritis. Arthritis and Rheumatism 2011 63 5 1211 1220 2-s2.0-79955562395 10.1002/art.30265
19. Gonzalez-Gay M. A., Gonzalez-Juanatey C., Lopez-Diaz M. J., Pieiro A., Garcia-Porrua C., Miranda-Filloy J. A., Ollier W. E. R., Martin J., Llorca J., HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis and Rheumatism 2007 57 1 125 132 2-s2.0-33846998295 10.1002/art.22482
20. Farragher T. M., Goodson N. J., Naseem H., Silman A. J., Thomson W., Symmons D., Barton A., Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis and Rheumatism 2008 58 2 359 369 2-s2.0-39749086221 10.1002/art.23149 (Pubitemid 351294870)
21. Mattey D. L., Thomson W., Ollier W. E. R., Barley M., Davies P. G., Gough A. K., Devlin J., Prouse P., James D. W., Williams P. L., Dixey J., Winfield J., Cox N. L., Koduri G., Young A., Association of DRB1 shared epitope genotypes with early mortality in rheumatoid arthritis: results of eighteen years of followup from the early rheumatoid arthritis study. Arthritis and Rheumatism 2007 56 5 1408 1416 2-s2.0-34248580624 10.1002/art.22527 (Pubitemid 46764067)
22. Gonzalez-Juanatey C., Testa A., Garcia-Castelo A., Garcia-Porrua C., Llorca J., Vidan J., Hajeer A. H., Ollier W. E., Mattey D. L., Gonzalez-Gay M. A., HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. The American Journal of Medicine 2003 114 8 647 652 2-s2.0-0038512497 10.1016/S0002-9343(03)00133-5 (Pubitemid 36703233)
23. Rojas-Villarraga A., Ortega-Hernandez O. D., Gomez L. F., Pardo A. L., López-Guzmán S., Arango-Ferreira C., Hincapie M. E., Betancur J. F., Pineda-Tamayo R., Diaz F. J., Anaya J. M., Risk factors associated with different stages of atherosclerosis in Colombian patients with rheumatoid arthritis. Seminars in Arthritis and Rheumatism 2008 38 2 71 82 2-s2.0-52149121712 10.1016/j.semarthrit.2008.01.019
24. Garcia-Bermudez M., González-Juanatey C., Lopez-Mejias R., Influence of MHCIITA rs3087456 and rs4774 polymorphisms in the susceptibility to cardiovascular disease of patients with rheumatoid arthritis. Clinical and Experimental Rheumatology 2012 30 51 57
25. Rodríguez-Rodríguez L., González-Juanatey C., Palomino-Morales R., Vázquez-Rodríguez T. R., Miranda-Filloy J. A., Fernández-Gutiérrez B., Llorca J., Martin J., González-Gay M. A., TNFA-308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis 2011 216 1 125 130 2-s2.0-79955531595 10.1016/j.atherosclerosis. 2010.10.052
26. Panoulas V. F., Nikas S. N., Smith J. P., Douglas K. M. J., Nightingale P., Milionis H. J., Treharne G. J., Toms T. E., Kita M. D., Kitas G. D., Lymphotoxin 252 A > G polymorphism is common and associates with myocardial infarction in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2008 67 11 1550 1556 2-s2.0-54349118740 10.1136/ard.2007.082594
27. Årlestig L., Jonsson S. W., Stegmayr B., Rantapää- Dahlqvist S., Polymorphism of genes related to cardiovascular disease in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology 2007 25 6 866 871 2-s2.0-38649102542 (Pubitemid 351166438)
28. Panoulas V. F., Stavropoulos-Kalinoglou A., Metsios G. S., Smith J. P., Milionis H. J., Douglas K. M. J., Nightingale P., Kitas G. D., Association of interleukin-6 (IL-6)-174G/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: the role of obesity and smoking. Atherosclerosis 2009 204 1 178 183 2-s2.0-67349084038 10.1016/j.atherosclerosis. 2008.08.036
29. López-Mejías R., García-Bermúdez M., González-Juanatey C., Castaeda S., Pérez-Esteban S., Miranda-Filloy J. A., Gómez-Vaquero C., Fernández-Gutiérrez B., Balsa A., Pascual-Salcedo D., Blanco R., González-álvaro I., Llorca J., Martín J., González-Gay M. A., Lack of association between IL6 single nucleotide polymorphisms and cardiovascular disease in Spanish patients with rheumatoid arthritis. Atherosclerosis 2011 219 2 655 658 2-s2.0-81155145461 10.1016/j.atherosclerosis.2011.07.124
30. Palomino-Morales R., Gonzalez-Juanatey C., Vazquez-Rodriguez T. R., Miranda-Filloy J. A., Llorca J., Martin J., Gonzalez-Gay M. A., Interleukin-6 gene -174 promoter polymorphism is associated with endothelial dysfunction but not with disease susceptibility in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology 2009 27 6 964 970 2-s2.0-76649083245
31. López-Mejías R., García-Bermúdez M., González-Juanatey C., Castaeda S., Miranda-Filloy J. A., Gómez-Vaquero C., Fernández-Gutiérrez B., Balsa A., Pascual-Salcedo D., Blanco R., González-Álvaro I., Llorca J., Martín J., González-Gay M. A., Lack of association of IL6R rs2228145 and IL6ST/gp130 rs2228044 gene polymorphisms with cardiovascular disease in patients with rheumatoid arthritis. Tissue Antigens 2011 78 6 438 441 2-s2.0-81155153686 10.1111/j.1399-0039.2011.01774.x
32. Radstake T. R. D. J., Fransen J., van Riel P. L. C. M., Toonen E., Coenen M., Donn R., Functional variants of the macrophage migration inhibitory factor do not infer risk of cardiovascular disease in rheumatoid arthritis. Annals of the Rheumatic Diseases 2008 67 1 134 135 2-s2.0-37749049216 10.1136/ard.2007. 079111
33. Palomino-Morales R., Gonzalez-Juanatey C., Vazquez-Rodriguez T. R., Torres O., Miranda-Filloy J. A., Llorca J., Martin J., Gonzalez-Gay M. A., Lack of association between macrophage migration inhibitory factor-173 gene polymorphism with disease susceptibility and cardiovascular risk in rheumatoid arthritis patients from northwestern Spain. Clinical and Experimental Rheumatology 2010 28 1 68 72 2-s2.0-77949521929
34. Rodríguez-Rodríguez L., González-Juanatey C., García-Bermúdez M., Vázquez-Rodríguez T. R., Miranda-Filloy J. A., Fernández-Gutiérrez B., Llorca J., Martin J., González-Gay M. A., CCR5Δ32 variant and cardiovascular disease in patients with rheumatoid arthritis: a cohort study. Arthritis Research and Therapy 2011 13 4, article R133 2-s2.0-80051636504 10.1186/ar3444
35. Farragher T. M., Plant D., Flynn E., Eyre S., Bunn D., Thomson W., Symmons D., Barton A., Association of a rheumatoid arthritis susceptibility variant at the CCL21 locus with premature mortality in inflammatory polyarthritis patients. Arthritis Care and Research 2010 62 5 676 682 2-s2.0-77951720878 10.1002/acr.20208
36. López-Mejías R., García-Bermúdez M., González-Juanatey C., Castaeda S., Miranda-Filloy J. A., Gómez-Vaquero C., Fernández-Gutiérrez B., Balsa A., Pascual-Salcedo D., Blanco R., González-Álvaro I., Llorca J., Martín J., González-Gay M. A., Lack of association between the CXCL12 rs501120 polymorphism and cardiovascular disease in Spanish patients with rheumatoid arthritis. Human Immunology 2012 73 5 543 546 2-s2.0-84860238371 10.1016/j.humimm.2012.02.012
37. Rodriguez-Rodriguez L., Garcia-Bermudez M., Gonzalez-Juanatey C., Vazquez-Rodriguez T. R., Miranda-Filloy J. A., Fernandez-Gutierrez B., Llorca J., Martin J., Gonzalez-Gay M. A., Lack of association between RETN rs1862513 polymorphism and cardiovascular disease in rheumatoid arthritis patients. Clinical and Experimental Rheumatology 2011 29 1 19 25 2-s2.0-79955650443
38. Rodríguez-Rodríguez L., García-Bermúdez M., González-Juanatey C., Vazquez-Rodriguez T. R., Miranda-Filloy J. A., Fernandez-Gutierrez B., Llorca J., Martin J., González-Gay M. A., Lack of association between ADIPOQ rs266729 and ADIPOQ rs1501299 polymorphisms and cardiovascular disease in rheumatoid arthritis patients. Tissue Antigens 2011 77 1 74 78 2-s2.0-78649997966 10.1111/j.1399-0039.2010.01580.x
39. García-Bermúdez M., González-Juanatey C., Rodríguez-Rodríguez L., Vazquez-Rodriguez T. R., Miranda-Filloy J. A., Fernández-Gutierrez B., Llorca J., Martin J., González-Gay M. A., Lack of association between LEP rs2167270 (19 G > A) polymorphism and disease susceptibility and cardiovascular disease in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology 2011 29 2 293 298 2-s2.0-79959516901
40. García-Bermúdez M., González-Juanatey C., Rodríguez-Rodríguez L., Miranda-Filloy J. A., Perez-Esteban S., Vazquez-Rodriguez T. R., Castaeda S., Balsa A., Fernández-Gutierrez B., Llorca J., González-Alvaro I., Martín J., González-Gay M. A., Lack of association of NAMPT rs9770242 and rs59744560 polymorphisms with disease susceptibility and cardiovascular risk in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology 2011 29 4 681 688 2-s2.0-80055096095
41. Gonzalez-Gay M. A., Llorca J., Palomino-Morales R., Gomez-Acebo I., Gonzales-Juanatey C., Martin J., Influence of nitric oxide synthase gene polymorphisms on the risk of cardiovasular events in rheumatoid arthritis. Clinical and Experimental Rheumatology 2009 27 1 116 119 2-s2.0-63049089491
42. Palomino-Morales R., Gonzalez-Juanatey C., Vazquez-Rodriguez T. R., Rodriguez L., Miranda-Filloy J. A., Pascual-Salcedo D., Balsa A., Fernandez-Gutierrez B., Llorca J., Martin J., Gonzalez-Gay M. A., Lack of association of PTPN22, STAT4 and TRAF1/C5 gene polymorphisms with cardiovascular risk in rheumatoid arthritis. Clinical and Experimental Rheumatology 2010 28 5 695 701 2-s2.0-78650526728
43. Palomino-Morales R., Gonzalez-Juanatey C., Vazquez-Rodriguez T. R., Rodriguez L., Miranda-Filloy J. A., Fernandez-Gutierrez B., Llorca J., Martin J., Gonzalez-Gay M. A., A1298C polymorphism in the MTHFR gene predisposes to cardiovascular risk in rheumatoid arthritis. Arthritis Research and Therapy 2010 12 2, article R71 2-s2.0-77951238604 10.1186/ar2989
44. Rodríguez-Rodríguez L., García-Bermúdez M., González-Juanatey C., Vazquez-Rodriguez T. R., Miranda-Filloy J. A., Fernández-Gutierrez B., Llorca J., Martín J., González-Gay M. A., Vascular endothelial growth factor A and cardiovascular disease in rheumatoid arthritis patients. Tissue Antigens 2011 77 4 291 297 2-s2.0-79952372070 10.1111/j.1399-0039.2010.01625.x
45. Rodríguez-Rodríguez L., García-Bermúdez M., Gonzalez-Juanatey C., Vazquez-Rodriguez T. R., Miranda-Filloy J. A., Fernandez-Gutierrez B., Llorca J., Martin J., Gonzalez-Gay M. A., Analysis of the influence of the ghrelin receptor rs509035, rs512692 and rs2922126 polymorphisms in the risk of cardiovascular disease in patients with rheumatoid arthritis. Clinical and experimental rheumatology 2011 29 1 142 143 2-s2.0-79955673714
46. García-Bermúdez M., López-Mejías R., González-Juanatey C., Lack of association between TLR4 rs4986790 polymorphism and risk of cardiovascular disease in patients with rheumatoid arthritis. DNA and Cell Biology 2012 31 7 1214 1220 10.1089/dna.2011.1582
47. Teruel M., Martin J. E., Gonzalez-Juanatey C., Lopez-Mejias R., Miranda-Filloy J. A., Blanco R., Balsa A., Pascual-Salcedo D., Rodriguez-Rodriguez L., Fernandez-Gutierrez B., Ortiz A. M., Gonzalez-Alvaro I., Gomez-Vaquero C., Bottini N., Llorca J., Gonzalez-Gay M. A., Martin J., Association of acid phosphatase locus 1C allele with the risk of cardiovascular events in rheumatoid arthritis patients. Arthritis Research & Therapy 2011 13, article R116 2-s2.0-79960554904 10.1186/ar3401
48. López-Mejías R., González-Juanatey C., García-Bermúdez M., Castaeda S., Miranda-Filloy J. A., Blanco R., Llorca J., Martín J., González-Gay M. A., The lp13.3 genomic region -rs599839- is associated with endothelial dysfunction in patients with rheumatoid arthritis. Arthritis Research and Therapy 2012 14 2, article R42 2-s2.0-84858447996 10.1186/ar3755
49. Gonzalez-Gay M. A., Gonzalez-Juanatey C., Ollier W. E., Endothelial dysfunction in rheumatoid arthritis: influence of HLA-DRB1 alleles. Autoimmunity Reviews 2004 3 4 301 304 2-s2.0-3142604996 10.1016/j.autrev.2003.10.006 (Pubitemid 38898665)
50. Gerli R., Bocci E. B., Sherer Y., Vaudo G., Moscatelli S., Shoenfeld Y., Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2008 67 5 724 725 2-s2.0-42449136119 10.1136/ard.2007.073718 (Pubitemid 351571944)
51. LeibundGut-Landmann S., Waldburger J. M., Krawczyk M., Otten L. A., Suter T., Fontana A., Acha-Orbea H., Reith W., Specificity and expression of CIITA, the master regulator of MHC class II genes. European Journal of Immunology 2004 34 6 1513 1525 2-s2.0-4544234467 10.1002/eji.200424964 (Pubitemid 39256032)
52. Butticè G., Miller J., Wang L., Smith B. D., Interferon- γ induces major histocompatibility class II transactivator (CIITA), which mediates collagen repression and major histocompatibility class II activation by human aortic smooth muscle cells. Circulation Research 2006 98 4 472 479 2-s2.0-33645294156 10.1161/01.RES.0000204725.46332.97
53. Swanberg M., Lidman O., Padyukov L., Eriksson P., Åkesson E., Jagodic M., Lobell A., Khademi M., Börjesson O., Lindgren C. M., Lundman P., Brookes A. J., Kere J., Luthman H., Alfredsson L., Hillert J., Klareskog L., Hamsten A., Piehl F., Olsson T., MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nature Genetics 2005 37 5 486 494 2-s2.0-20944445879 10.1038/ng1544 (Pubitemid 40617276)
54. Bouma G., Crusius J. B. A., Oudkerk Pool M., Kolkman J. J., Von Blomberg B. M. E., Kostense P. J., Giphart M. J., Schreuder G. M. T., Meuwissen S. G. M., Pea A. S., Secretion of tumour necrosis factor α and lymphotoxin α in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scandinavian Journal of Immunology 1996 43 4 456 463 2-s2.0-9244244710 (Pubitemid 26104933)
55. Elahi M. M., Asotra K., Matata B. M., Mastana S. S., Tumor necrosis factor α 308 gene locus promoter polymorphism: an analysis of association with health and disease. Biochimica et Biophysica Acta 2009 1792 3 163 172 2-s2.0-61349179432 10.1016/j.bbadis.2009.01.007
56. Kaijzel E. L., Bayley J. P., van Krugten M. V., Smith L., van de Linde P., Bakker A. M., Breedveld F. C., Huizinga T. W. J., Verweij C. L., Allele-specific quantification of tumor necrosis factor α (TNF) transcription and the role of promoter polymorphisms in rheumatoid arthritis patients and healthy individuals. Genes and Immunity 2001 2 3 135 144 2-s2.0-0035348006 10.1038/sj.gene.6363747 (Pubitemid 33674878)
57. Vallvé J. C., Paredes S., Girona J., Uliaque K., Ribalta J., Hurt-Camejo E., Masana L., Tumor necrosis factor- α -1031 T/C polymorphism is associated with smaller and more proatherogenic low density lipoprotein particles in patients with rheumatoid arthritis. Journal of Rheumatology 2008 35 9 1697 1703 2-s2.0-54049115585
58. Tanaka T., Ozaki K., Inflammation as a risk factor for myocardial infarction. Journal of Human Genetics 2006 51 7 595 604 2-s2.0-33745914670 10.1007/s10038-006-0411-8 (Pubitemid 44048692)
59. Schreyer S. A., Vick C. M., Leboeuf R. C., Loss of lymphotoxin- α but not tumor necrosis factor- α reduces atherosclerosis in mice. The Journal of Biological Chemistry 2002 277 14 12364 12368 2-s2.0-0037023783 10.1074/jbc.M111727200 (Pubitemid 34952808)
60. Ozaki K., Inoue K., Sato H., Iida A., Ohnishi Y., Sekine A., Sato H., Odashiro K., Hobuyoshi M., Hori M., Nakamura Y., Tanaka T., Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin- α secretion in vitro. Nature 2004 429 6987 72 75 2-s2.0-2342480580 10.1038/nature02502 (Pubitemid 38620552)
61. Panoulas V. F., Douglas K. M. J., Smith J. P., Metsios G. S., Elisaf M. S., Nightingale P., Kitas G. D., Galectin-2 (LGALS2) 3279C/T polymorphism may be independently associated with diastolic blood pressure in patients with rheumatoid arthritis. Clinical and Experimental Hypertension 2009 31 2 93 104 2-s2.0-66949120742 10.1080/10641960802621267
62. Papanicolaou D. A., Wilder R. L., Manolagas S. C., Chrousos G. P., The pathophysiologic roles of interleukin-6 in human disease. Annals of Internal Medicine 1998 128 2 127 137 2-s2.0-0031963046 (Pubitemid 28053135)
63. Houssiau F. A., Devogelaer J. P., van Damme J., Nagant de Deuxchaisnes C., van Snick J., Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis and Rheumatism 1988 31 6 784 788 2-s2.0-0023942493
64. Danesh J., Kaptoge S., Mann A. G., Sarwar N., Wood A., Angleman S. B., Wensley F., Higgins J. P. T., Lennon L., Eiriksdottir G., Rumley A., Whincup P. H., Lowe G. D. O., Gudnason V., Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Medicine 2008 5 4, article e78 2-s2.0-43249118045 10.1371/journal.pmed.0050078 (Pubitemid 351649259)
65. Dessein P. H., Joffe B. I., Singh S., Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Research & Therapy 2005 7 3 R634 R643 2-s2.0-28444457810
66. Dessein P. H., Joffe B. I., Suppression of circulating interleukin-6 concentrations is associated with decreased endothelial activation in rheumatoid arthritis. Clinical and Experimental Rheumatology 2006 24 2 161 167 2-s2.0-33744808528 (Pubitemid 43826865)
67. Jones K. G., Brull D. J., Brown L. C., Sian M., Greenhalgh R. M., Humphries S. E., Powell J. T., Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation 2001 103 18 2260 2265 2-s2.0-0035826716 (Pubitemid 32433715)
68. Panoulas V. F., Douglas K. M. J., Smith J. P., Stavropoulos-Kalinoglou A., Metsios G. S., Nightingale P., Kitas G. D., Transforming growth factor- β 1 869T/C, but not interleukin-6 -174G/C, polymorphism associates with hypertension in rheumatoid arthritis. Rheumatology 2009 48 2 113 118 2-s2.0-58949083368 10.1093/rheumatology/ken443
69. Galicia J. C., Tai H., Komatsu Y., Shimada Y., Akazawa K., Yoshie H., Polymorphisms in the IL-6 receptor (IL-6R) gene: strong evidence that serum levels of soluble IL-6R are genetically influenced. Genes and Immunity 2004 5 6 513 516 2-s2.0-4644371697 10.1038/sj.gene.6364120 (Pubitemid 39263887)
70. Rodríguez-Rodríguez L., Lamas J. R., Varadé J., López-Romero P., Tornero-Esteban P., Abasolo L., de La Concha E. G., Jover J. A., Urcelay E., Fernández-Gutiérrez B., Plasma soluble IL-6 receptor concentration in rheumatoid arthritis: associations with the rs8192284 IL6R polymorphism and with disease activity. Rheumatology International 2011 31 3 409 413 2-s2.0-79954435661 10.1007/s00296-010-1593-0
71. Sarwar N., Butterworth A. S., Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. The Lancet 2012 379 9822 1205 1213 2-s2.0-84859210770 10.1016/S0140-6736(11)61931-4
72. Santos L. L., Morand E. F., Macrophage migration inhibitory factor: a key cytokine in RA, SLE and atherosclerosis. Clinica Chimica Acta 2009 399 1-2 1 7 2-s2.0-57049184633 10.1016/j.cca.2008.09.014
73. Radstake T. R. D. J., Sweep F. C. G. J., Welsing P., Franke B., Vermeulen S. H. H. M., Geurts-Moespot A., Calandra T., Donn R., van Riel P. L. C. M., Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis and Rheumatism 2005 52 10 3020 3029 2-s2.0-26844555755 10.1002/art.21285 (Pubitemid 41447081)
74. Jones K. L., Maguire J. J., Davenport A. P., Chemokine receptor CCR5: from AIDS to atherosclerosis. British Journal of Pharmacology 2011 162 7 1453 1469 2-s2.0-79952385006 10.1111/j.1476-5381.2010.01147.x
75. Samson M., Libert F., Doranz B. J., Rucker J., Liesnard C., Farber M., Saragosti S., Lapoumeroulie C., Cognaux J., Forceille C., Muyldermans G., Verhofstede C., Burtonboy G., Georges M., Imai T., Rana S., Yi Y., Smyth R. J., Parmentier M., Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996 382 6593 722 725 2-s2.0-16044373004 10.1038/382722a0 (Pubitemid 26282179)
76. Benkirane M., Jin D. Y., Chun R. F., Koup R. A., Jeang K. T., Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5Δ32. The Journal of Biological Chemistry 1997 272 49 30603 30606 2-s2.0-0030712312 10.1074/jbc.272.49.30603 (Pubitemid 27527488)
77. Pacheco S. E., Gibbs R. A., Ansari-Lari A., Rogers P., Intranasal immunization with HIV reverse transcriptase: effect of dose in the induction of helper T cell type 1 and 2 immunity. AIDS Research and Human Retroviruses 2000 16 18 2009 2017 2-s2.0-0034634906 10.1089/088922200750054747 (Pubitemid 32048459)
78. Balistreri C. R., Candore G., Caruso M., Incalcaterra E., Franceschi C., Caruso C., Role of polymorphisms of CC-chemokine receptor-5 gene in acute myocardial infarction and biological implications for longevity. Haematologica 2008 93 4 637 638 2-s2.0-42149116900 10.3324/haematol.12239 (Pubitemid 351536399)
79. Pai J. K., Kraft P., Cannuscio C. C., Manson J. E., Rexrode K. M., Albert C. M., Hunter D., Rimm E. B., Polymorphisms in the CC-chemokine receptor-2 (CCR2) and -5 (CCR5) genes and risk of coronary heart disease among US women. Atherosclerosis 2006 186 1 132 139 2-s2.0-33645889658 10.1016/j.atherosclerosis. 2005.06.041
80. Manzo A., Paoletti S., Carulli M., Blades M. C., Barone F., Yanni G., FitzGerald O., Bresnihan B., Caporali R., Montecucco C., Uguccioni M., Pitzalis C., Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis. European Journal of Immunology 2005 35 5 1347 1359 2-s2.0-21044435315 10.1002/eji.200425830 (Pubitemid 40691416)
81. Trogan E., Feig J. E., Dogan S., Rothblat G. H., Angeli V., Tacke F., Randolph G. J., Fisher E. A., Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proceedings of the National Academy of Sciences of the United States of America 2006 103 10 3781 3786 2-s2.0-33644852050 10.1073/pnas.0511043103 (Pubitemid 43376632)
82. Abi-Younes S., Sauty A., Mach F., Sukhova G. K., Libby P., Luster A. D., The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circulation Research 2000 86 2 131 138 2-s2.0-0033964318 (Pubitemid 30086172)
83. Burton P. R., Clayton D. G., Cardon L. R., Craddock N., Deloukas P., Duncanson A., Kwiatkowski D. P., McCarthy M. I., Ouwehand W. H., Samani N. J., Todd J. A., Donnelly P., Barrett J. C., Davison D., Easton D., Evans D., Leung H. T., Marchini J. L., Morris A. P., Spencer C. C. A., Tobin M. D., Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007 447 7145 661 678 2-s2.0-34250025139 10.1038/nature05911 (Pubitemid 46889737)
84. Trayhurn P., Wood I. S., Adipokines: inflammation and the pleiotropic role of white adipose tissue. The British Journal of Nutrition 2004 92 3 347 355 2-s2.0-6944237757 10.1079/BJN20041213 (Pubitemid 40277057)
85. Solomon A., Norton G. R., Woodiwiss A. J., Dessein P. H., Obesity and carotid atherosclerosis in African black and Caucasian women with established rheumatoid arthritis: a cross-sectional study. Arthritis Research and Therapy 2012 14 2 R67 2-s2.0-84858330240 10.1186/ar3784
86. Reilly M. P., Lehrke M., Wolfe M. L., Rohatgi A., Lazar M. A., Rader D. J., Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005 111 7 932 939 2-s2.0-14044257211 10.1161/01.CIR.0000155620.10387.43 (Pubitemid 40279897)
87. Gonzalez-Gay M. A., Garcia-Unzueta M. T., Gonzalez-Juanatey C., Miranda-Filloy J. A., Vazquez-Rodriguez T. R., de Matias J. M., Martin J., Dessein P. H., Llorca J., Anti-TNF- α therapy modulates resistin in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology 2008 26 2 311 316 2-s2.0-43349098447 (Pubitemid 351659139)
88. Tsukahara T., Nakashima E., Watarai A., Hamada Y., Naruse K., Kamiya H., Nakamura N., Kato N., Hamajima N., Sekido Y., Niwa T., Tomita M., Oiso Y., Nakamura J., Polymorphism in resistin promoter region at -420 determines the serum resistin levels and may be a risk marker of stroke in Japanese type 2 diabetic patients. Diabetes Research and Clinical Practice 2009 84 2 179 186 2-s2.0-63649135069 10.1016/j.diabres.2008.10.021
89. Kunnari A., Ukkola O., Kesäniemi Y. A., Resistin polymorphisms are associated with cerebrovascular disease in Finnish type 2 diabetic patients. Diabetic Medicine 2005 22 5 583 589 2-s2.0-17844373585 10.1111/j.1464-5491.2005. 01480.x (Pubitemid 40593134)
90. Hoffmann M. M., Pilz S., Weihrauch G., Seelhorst U., Wellnitz B., Winkelmann B. R., Boehm B. O., März W., Effect of the resistin -420 C > G polymorphism on cardiovascular disease and mortality. Clinical Endocrinology 2008 69 2 344 345 2-s2.0-47549114697 10.1111/j.1365-2265.2007.03163.x (Pubitemid 352009011)
91. Qasim A. N., Metkus T. S., Tadesse M., Lehrke M., Restine S., Wolfe M. L., Hannenhalli S., Cappola T., Rader D. J., Reilly M. P., Resistin gene variation is associated with systemic inflammation but not plasma adipokine levels, metabolic syndrome or coronary atherosclerosis in nondiabetic Caucasians. Clinical Endocrinology 2009 70 5 698 705 2-s2.0-63149193465 10.1111/j.1365-2265.2008.03375.x
92. Ouchi N., Kihara S., Arita Y., Nishida M., Matsuyama A., Okamoto Y., Ishigami M., Kuriyama H., Kishida K., Nishizawa H., Hotta K., Muraguchi M., Ohmoto Y., Yamashita S., Funahashi T., Matsuzawa Y., Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001 103 8 1057 1063 2-s2.0-0035957040 (Pubitemid 32200177)
93. Frystyk J., Berne C., Berglund L., Jensevik K., Flyvbjerg A., Zethelius B., Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. Journal of Clinical Endocrinology and Metabolism 2007 92 2 571 576 2-s2.0-33846982934 10.1210/jc.2006-1067
94. Choi H. M., Lee Y. A., Lee S. H., Hong S. J., Hahm D. H., Choi S. Y., Yang H. I., Yoo M. C., Kim K. S., Adiponectin may contribute to synovitis and joint destruction in rheumatoid arthritis by stimulating vascular endothelial growth factor, matrix metalloproteinase-1, and matrix metalloproteinase-13 expression in fibroblast-like synoviocytes more than proinflammatory mediators. Arthritis Research and Therapy 2009 11 6, article R161 2-s2.0-77952490138 10.1186/ar2844
95. Giles J. T., van der Heijde D. M., Bathon J. M., Association of circulating adiponectin levels with progression of radiographic joint destruction in rheumatoid arthritis. Annals of the Rheumatic Diseases 2011 70 9 1562 1568 2-s2.0-79955813917 10.1136/ard.2011.150813
96. Gonzalez-Gay M. A., Llorca J., Garcia-Unzueta M. T., Gonzalez-Juanatey C., de Matias J. M., Martin J., Redelinghuys M., Woodiwiss A. J., Norton G. R., Dessein P. H., High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis. Clinical and Experimental Rheumatology 2008 26 4 596 603 2-s2.0-52649173297
97. Heid I. M., Henneman P., Hicks A., Coassin S., Winkler T., Aulchenko Y. S., Fuchsberger C., Song K., Hivert M. F., Waterworth D. M., Timpson N. J., Richards J. B., Perry J. R. B., Tanaka T., Amin N., Kollerits B., Pichler I.,
98. Han L. Y., Wu Q. H., Jiao M. L., Hao Y. H., Liang L. B., Gao L. J., Legge D. G., Quan H., Zhao M. M., Ning N., Kang Z., Sun H., Associations between single-nucleotide polymorphisms (+45 T > G, +276 G > G, -11377 C > G, -11391 G > A) of adiponectin gene and type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetologia 2011 54 9 2303 2314 2-s2.0-79957650197 10.1007/s00125-011-2202-9
99. Liu F., He Z., Deng S., Zhang H., Li N., Xu J., Association of adiponectin gene polymorphisms with the risk of ischemic stroke in a Chinese Han population. Molecular Biology Reports 2011 38 3 1983 1988 2-s2.0-79951580076 10.1007/s11033-010-0320-y
100. Hoefle G., Muendlein A., Saely C. H., Risch L., Rein P., Koch L., Schmid F., Aczel S., Marte T., Langer P., Drexel H., The -11377 C > G promoter variant of the adiponectin gene, prevalence of coronary atherosclerosis, and incidence of vascular events in men. Thrombosis and Haemostasis 2007 97 3 451 457 2-s2.0-33947301943 10.1160/TH06-11-0646 (Pubitemid 46437808)
101. Gable D. R., Matin J., Whittall R., Cakmak H., Li K. W., Cooper J., Miller G. J., Humphries S. E., Hamsten A., Juhan-Vague I., Margaglione M., di Minno G., Yudkin J., Tremoli E., Common adiponectin gene variants show different effects on risk of cardiovascular disease and type 2 diabetes in European subjects. Annals of Human Genetics 2007 71 4 453 466 2-s2.0-33947583511 10.1111/j.1469-1809.2006.00340.x (Pubitemid 46865494)
102. Patel S., Flyvbjerg A., Kozàkovà M., Variation in the ADIPOQ gene promoter is associated with carotid intima media thickness independent of plasma adiponectin levels in healthy subjects. European Heart Journal 2008 29 3 386 393 (Pubitemid 351197748)
103. Chiodini B. D., Specchia C., Gori F., Barlera S., D'Orazio A., Pietri S., Crociati L., Nicolucci A., Franciosi M., Signorini S., Brambilla P., Grazia Franzosi M., Adiponectin gene polymorphisms and their effect on the risk of myocardial infarction and type 2 diabetes: an association study in an Italian population. Therapeutic Advances in Cardiovascular Disease 2010 4 4 223 230 2-s2.0-77955412260 10.1177/1753944710371483
104. Menzaghi C., Trischitta V., Doria A., Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease. Diabetes 2007 56 5 1198 1209 2-s2.0-34248187069 10.2337/db06-0506 (Pubitemid 46715598)
105. Tong K. M., Shieh D. C., Chen C. P., Tzeng C. Y., Wang S. P., Huang K. C., Chiu Y. C., Fong Y. C., Tang C. H., Leptin induces IL-8 expression via leptin receptor, IRS-1, PI3K, Akt cascade and promotion of NF- κ B/p300 binding in human synovial fibroblasts. Cellular Signalling 2008 20 8 1478 1488 2-s2.0-45449105340 10.1016/j.cellsig.2008.04.003
106. Galletti F., Barbato A., Versiero M., Iacone R., Russo O., Barba G., Siani A., Cappuccio F. P., Farinaro E., Valle E. D., Strazzullo P., Circulating leptin levels predict the development of metabolic syndrome in middle-aged men: an 8-year follow-up study. Journal of Hypertension 2007 25 8 1671 1677 2-s2.0-34447322539 10.1097/HJH.0b013e3281afa09e (Pubitemid 47056575)
107. Otero M., Lago R., Gomez R., Lago F., Dieguez C., Gómez-Reino J. J., Gualillo O., Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2006 65 9 1198 1201 2-s2.0-33747786726 10.1136/ard.2005.046540 (Pubitemid 44277396)
108. Gonzalez-Gay M. A., Garcia-Unzueta M. T., Berja A., Gonzalez-Juanatey C., Miranda-Filloy J. A., Vazquez-Rodriguez T. R., Matias J. M. D., Martin J., Dessein P. H., Llorca J., Anti-TNF- α therapy does not modulate leptin in patients with severe rheumatoid arthritis. Clinical and Experimental Rheumatology 2009 27 2 222 228 2-s2.0-67249123828
109. Hager J., Clement K., Francke S., Dina C., Raison J., Lahlou N., Rich N., Pelloux V., Basdevant A., Guy-Grand B., North M., Froguel P., A polymorphism in the 5′ untranslated region of the human ob gene is associated with low leptin levels. International Journal of Obesity 1998 22 3 200 205 2-s2.0-2342609965 (Pubitemid 28112018)
110. Li W. D., Reed D. R., Lee J. H., Xu W., Kilker R. L., Sodam B. R., Price R. A., Sequence variants in the 5′ flanking region of the leptin gene are associated with obesity in women. Annals of Human Genetics 1999 63 3 227 234 2-s2.0-0032871802 10.1017/S0003480099007496 (Pubitemid 29471966)
111. Brentano F., Schorr O., Ospelt C., Stanczyk J., Gay R. E., Gay S., Kyburz D., Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis and Rheumatism 2007 56 9 2829 2839 2-s2.0-34848847894 10.1002/art.22833 (Pubitemid 47502729)
112. Dahl T. B., Yndestad A., Skjelland M., Oie E., Dahl A., Michelsen A., Damås J. K., Tunheim S. H., Ueland T., Smith C., Bendz B., Tonstad S., Gullestad L., Froland S. S., Krohg-Sorensen K., Russell D., Aukrust P., Halvorsen B., Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 2007 115 8 972 980 2-s2.0-33847279330 10.1161/CIRCULATIONAHA.106.665893 (Pubitemid 46328290)
113. Bailey S. D., Loredo-Osti J. C., Lepage P., Faith J., Fontaine J., Desbiens K. M., Hudson T. J., Bouchard C., Gaudet D., Pérusse L., Vohl M. C., Engert J. C., Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels in a French-Canadian population. Diabetes 2006 55 10 2896 2902 2-s2.0-33750862924 10.2337/db06-0189 (Pubitemid 44923693)
114. Johansson L. M., Johansson L. E., Ridderstråle M., The visfatin (PBEF1) G-948T gene polymorphism is associated with increased high-density lipoprotein cholesterol in obese subjects. Metabolism 2008 57 11 1558 1562 2-s2.0-53649107774 10.1016/j.metabol.2008.06.011
115. Gonzalez-Gay M. A., Vazquez-Rodriguez T. R., Garcia-Unzueta M. T., Berja A., Miranda-Filloy J. A., de Matias J. M., Gonzalez-Juanatey C., Llorca J., Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF- α therapy. Clinical and Experimental Rheumatology 2010 28 1 56 62 2-s2.0-77949508778
116. Chatterjee A., Catravas J. D., Endothelial nitric oxide (NO) and its pathophysiologic regulation. Vascular Pharmacology 2008 49 46 134 140 2-s2.0-50149087550 10.1016/j.vph.2008.06.008
117. Casas J. P., Cavalleri G. L., Bautista L. E., Smeeth L., Humphries S. E., Hingorani A. D., Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGE review. American Journal of Epidemiology 2006 164 10 921 935 2-s2.0-33750903351 10.1093/aje/kwj302 (Pubitemid 44729832)
118. Kawaguchi Y., Kawaguchi Y., Hara M., Kawamoto M., Sugiura T., Katsumata Y., Okada J., Kondo H., Okubo M., Kamatani N., NOS2 polymorphisms associated with the susceptibility to pulmonary arterial hypertension with systemic sclerosis: contribution to the transcriptional activity. Arthritis Research and Therapy 2006 8 4, article R104 2-s2.0-70449586522 10.1186/ar1984
119. Huber K., Christ G., Wojta J., Gulba D., Plasminogen activator inhibitor type-1 in cardiovascular diseasestatus report 2001. Thrombosis Research 2001 103 supplement 1 S7 S19 2-s2.0-0035975586 10.1016/S0049-3848(01)00293-6 (Pubitemid 32913248)
120. Tsantes A. E., Nikolopoulos G. K., Bagos P. G., Bonovas S., Kopterides P., Vaiopoulos G., The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk. Thrombosis Research 2008 122 6 736 742 2-s2.0-52249094419 10.1016/j.thromres.2007.09.005
121. Board P. G., Webb G. C., McKee J., Ichinose A., Localization of the coagulation factor XIII A subunit gene (F13A) to chromosome bands 6p 24 → p 25. Cytogenetics and Cell Genetics 1988 48 1 25 27 2-s2.0-0023685125 (Pubitemid 18265292)
122. Trumbo T. A., Maurer M. C., Examining thrombin hydrolysis of the factor XIII activation peptide segment leads to a proposal for explaining the cardioprotective effects observed with the factor XIII V34L mutation. The Journal of Biological Chemistry 2000 275 27 20627 20631 2-s2.0-0034617203 10.1074/jbc.M000209200 (Pubitemid 30457648)
123. Tousoulis D., Papageorgiou N., Androulakis E., Briasoulis A., Antoniades C., Stefanadis C., Fibrinogen and cardiovascular disease: genetics and biomarkers. Blood Reviews 2011 25 6 239 245 2-s2.0-79957846242 10.1016/j.blre.2011.05.001
124. Paraskevas K. I., Baker D. M., Vrentzos G. E., Mikhailidis D. P., The role of fibrinogen and fibrinolysis in peripheral arterial disease. Thrombosis Research 2008 122 1 1 12 2-s2.0-42949172414 10.1016/j.thromres.2007.06.003 (Pubitemid 351618332)
125. van Nies J. A. B., Marques R. B., Trompet S., de Jong Z., Kurreeman F. A. S., Toes R. E. M., Jukema J. W., Huizinga T. W. J., van der Helm-van Mil A. H. M., TRAF1/C5 polymorphism is not associated with increased mortality in rheumatoid arthritis: two large longitudinal studies. Arthritis Research and Therapy 2010 12 2, article R38 2-s2.0-77955279795 10.1186/ar2947
126. Hernanz A., Plaza A., Martín-Mola E., de Miguel E., Increased plasma levels of homocysteine and other thiol compounds in rheumatoid arthritis women. Clinical Biochemistry 1999 32 1 65 70 2-s2.0-0033011245 10.1016/S0009-9120(98)00093-9 (Pubitemid 29095768)
127. Frosst P., Blom H. J., Milos R., Goyette P., Sheppard C. A., Matthews R. G., Boers G. J. H., den Heijer M., Kluijtmans L. A. J., van den Heuvel L. P., Rozen R., A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genetics 1995 10 1 111 113 2-s2.0-0029049553
128. Weisberg I., Tran P., Christensen B., Sibani S., Rozen R., A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Molecular Genetics and Metabolism 1998 64 3 169 172 2-s2.0-0031687887 10.1006/mgme.1998.2714 (Pubitemid 28453294)
129. Ribatti D., Levi-Schaffer F., Kovanen P. T., Inflammatory angiogenesis in atherogenesisa double-edged sword. Annals of Medicine 2008 40 8 606 621 2-s2.0-56849103111 10.1080/07853890802186913
130. Dor Y., Porat R., Keshet E., Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. American Journal of Physiology 2001 280 6 C1367 C1374 2-s2.0-0034979159 (Pubitemid 32553191)
131. Frantz S., Vincent K. A., Feron O., Kelly R. A., Innate immunity and angiogenesis. Circulation Research 2005 96 1 15 26 2-s2.0-11844251984 10.1161/01.RES.0000153188.68898.ac (Pubitemid 40095751)
132. Lambrechts D., Storkebaum E., Morimoto M., del-Favero J., Desmet F., Marklund S. L., Wyns S., Thijs V., Andersson J., van Marion I., Al-Chalabi A., Bornes S., Musson R., Hansen V., Beckman L., Adolfsson R., Pall H. S., Prats H., Vermeire S., Rutgeerts P., Katayama S., Awata T., Leigh N., Lang-Lazdunski L., Dewerchin M., Shaw C., Moons L., Vlietinck R., Morrison K. E., Robberecht W., van Broeckhoven C., Collen D., Andersen P. M., Carmeliet P., VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nature Genetics 2003 34 4 383 394 2-s2.0-0041903805 10.1038/ng1211 (Pubitemid 36935331)
133. Petrovi D., Verhovec R., Globonik Petrovi M., Osredkar J., Peterlin B., Association of vascular endothelial growth factor gene polymorphism with myocardial infarction in patients with type 2 diabetes. Cardiology 2007 107 4 291 295 2-s2.0-34249045423 10.1159/000099064 (Pubitemid 46788246)
134. Salvarani C., Boiardi L., Casali B., Olivieri I., Cantini F., Salvi F., Malatesta R., La Corte R., Triolo G., Ferrante A., Filippini D., Paolazzi G., Sarzi-Puttini P., Nicoli D., Farnetti E., Chen Q., Pulsatelli L., Vascular endothelial growth factor gene polymorphisms in Behet's disease. Journal of Rheumatology 2004 31 9 1785 1789 2-s2.0-4444316669 (Pubitemid 39202522)
135. Boiardi L., Casali B., Nicoli D., Farnetti E., Chen Q., Macchioni P., Catanoso M. G., Pulsatelli L., Meliconi R., Salvarani C., Vascular endothelial growth factor gene polymorphisms in giant cell arteritis. Journal of Rheumatology 2003 30 10 2160 2164 2-s2.0-10744228051 (Pubitemid 37221846)
136. Rueda B., Lopez-Nevot M. A., Lopez-Diaz M. J., Garcia-Porrua C., Martín J., Gonzalez-Gay M. A., A functional variant of vascular endothelial growth factor is associated with severe ischemic complications in giant cell arteritis. Journal of Rheumatology 2005 32 9 1737 1741 2-s2.0-24944519879 (Pubitemid 41324813)
137. Howell W. M., Ali S., Rose-Zerilli M. J., Ye S., VEGF polymorphisms and severity of atherosclerosis. Journal of Medical Genetics 2005 42 6 485 490 2-s2.0-20544434319 10.1136/jmg.2004.025734 (Pubitemid 40847236)
138. Smith R. G., Jiang H., Sun Y., Developments in ghrelin biology and potential clinical relevance. Trends in Endocrinology and Metabolism 2005 16 9 436 442 2-s2.0-27144468685 10.1016/j.tem.2005.09.004 (Pubitemid 41506951)
139. Dixit V. D., Schaffer E. M., Pyle R. S., Collins G. D., Sakthivel S. K., Palaniappan R., Lillard J. W., Taub D. D., Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. The Journal of Clinical Investigation 2004 114 1 57 66 2-s2.0-3242749843 10.1172/JCI200421134 (Pubitemid 39071644)
140. Li W. G., Gavrila D., Liu X., Wang L., Gunnlaugsson S., Stoll L. L., McCormick M. L., Sigmund C. D., Tang C., Weintraub N. L., Ghrelin inhibits proinflammatory responses and nuclear factor- κ B activation in human endothelial cells. Circulation 2004 109 18 2221 2226 2-s2.0-2442419837 10.1161/01.CIR.0000127956.43874.F2 (Pubitemid 38625400)
141. Gonzalez-Gay M. A., Garcia-Unzueta M. T., Berja A., Vazquez-Rodriguez T. R., Gonzalez-Juanatey C., de Matias J. M., Martin J., Dessein P. H., Llorca J., Anti-tumour necrosis factor α therapy modulates ghrelin in patients with severe rheumatoid arthritis. Annals of the Rheumatic Diseases 2008 67 11 1644 1646 2-s2.0-54349118245 10.1136/ard.2008.088773
142. Robledo G., Rueda B., Gonzalez-Gay M. A., Fernández B., Lamas J. R., Balsa A., Pascual-Salcedo D., García A., Raya E., Martín J., Association study of ghrelin receptor gene polymorphisms in rheumatoid arthritis. Clinical and Experimental Rheumatology 2010 28 1 25 29 2-s2.0-77949511307
143. Baessler A., Fischer M., Mayer B., Koehler M., Wiedmann S., Stark K., Doering A., Erdmann J., Riegger G., Schunkert H., Kwitek A. E., Hengstenberg C., Epistatic interaction between haplotypes of the ghrelin ligand and receptor genes influence susceptibility to myocardial infarction and coronary artery disease. Human Molecular Genetics 2007 16 8 887 899 2-s2.0-34447298876 10.1093/hmg/ddm033 (Pubitemid 47062734)
144. Michelsen K. S., Wong M. H., Shah P. K., Zhang W., Yano J., Doherty T. M., Akira S., Rajavashisth T. B., Arditi M., Lack of toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proceedings of the National Academy of Sciences of the United States of America 2004 101 29 10679 10684 2-s2.0-3242710174 10.1073/pnas.0403249101 (Pubitemid 38955802)
145. Arbour N. C., Lorenz E., Schutte B. C., Zabner J., Kline J. N., Jones M., Frees K., Watt J. L., Schwartz D. A., TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nature Genetics 2000 25 2 187 191 2-s2.0-0034084438 10.1038/76048 (Pubitemid 30394990)
146. Steinhardt A. P., Aranguren F., Tellechea M. L., Gómez Rosso L. A., Brites F. D., Martínez-Larrad M. T., Serrano-Ríos M., Frechtel G. D., Taverna M. J., A functional nonsynonymous toll-like receptor 4 gene polymorphism is associated with metabolic syndrome, surrogates of insulin resistance, and syndromes of lipid accumulation. Metabolism 2010 59 5 711 717 2-s2.0-77950792795 10.1016/j.metabol.2009.09.015
147. Souza A. C. S., Azoubel S., Queiroz K. C. S., Peppelenbosch M. P., Ferreira C. V., From immune response to cancer: a spot on the low molecular weight protein tyrosine phosphatase. Cellular and Molecular Life Sciences 2009 66 7 1140 1153 2-s2.0-63449129930 10.1007/s00018-008-8501-8
148. Banci M., Saccucci P., D'Annibale F., Dofcaci A., Trionfera G., Magrini A., Bottini N., Bottini E., Gloria-Bottini F., ACP1 genetic polymorphism and coronary artery disease: an association study. Cardiology 2009 113 4 236 242 2-s2.0-60749089388 10.1159/000203405
149. Samani N. J., Erdmann J., Hall A. S., Hengstenberg C., Mangino M., Mayer B., Dixon R. J., Meitinger T., Braund P., Wichmann H.-E., Barrett J. H., König I. R., Stevens S. E., Szymczak S., Tregouet D.-A., Iles M. M., Pahlke F., Pollard H., Lieb W., Cambien F., Fischer M., Ouwehand W., Blankenberg S., Balmforth A. J., Baessler A., Ball S. G., Strom T. M., Brænne I., Gieger C., Deloukas P., Tobin M. D., Ziegler A., Thompson J. R., Schunkert H., Genomewide association analysis of coronary artery disease. The New England Journal of Medicine 2007 357 5 443 453 2-s2.0-34547623750 10.1056/NEJMoa072366 (Pubitemid 47204873)
150. Jorgensen T. J., Ruczinski I., Kessing B., Smith M. W., Shugart Y. Y., Alberg A. J., Hypothesis-driven candidate gene association studies: practical design and analytical considerations. American Journal of Epidemiology 2009 170 8 986 993 2-s2.0-70349685090 10.1093/aje/kwp242